A pharmacokinetic and pharmacodynamic study of Maraviroc as cute graft-versus-host disease prophylaxis in pediatric allogeneic stem cell transplant recipients with nonmalignant diagnoses.
Phase of Trial: Phase IV
Latest Information Update: 13 Feb 2018
At a glance
- Drugs Maraviroc (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 13 Feb 2018 New trial record